Lercanidipine: A Review of its Efficacy in the Management of Hypertension

Drugs

Volumn 63, Issue 22, 2003, Pages 2449-2472

  Bang, Lynne M ^a   Chapman, Therese M ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Hypertension; Lercanidipine; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM ION; CAPTOPRIL; CIMETIDINE; CYCLOSPORIN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; FLUOXETINE; HYDROCHLOROTHIAZIDE; KETOCONAZOLE; LACIDIPINE; LERCANIDIPINE; METILDIGOXIN; METOPROLOL; MIDAZOLAM; NIFEDIPINE; NITRENDIPINE; PLACEBO; SILDENAFIL; SIMVASTATIN; VERAPAMIL; WARFARIN;

ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ATHEROGENESIS; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; ELDERLY CARE; ESSENTIAL HYPERTENSION; FIRST PASS EFFECT; FLUSHING; GLUCOSE METABOLISM; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIPID METABOLISM; LIPOPHILICITY; LIVER DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; POSTMENOPAUSE; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; VASODILATATION; VERTIGO;

CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; DIHYDROPYRIDINES; DRUG INTERACTIONS; HUMANS; HYPERTENSION;

EID: 0242609349     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363220-00013     Document Type: Review

References (82)

1. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13
2. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-13
3. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16: 747-52
4. Scriabine A. Seventeenth annual scientific meeting of the American Society of Hypertension, New York, NY, May 14-18. 2002. Cardiovasc Drug Rev 2002; 20 (2): 153-61
5. McClellan KJ, Jarvis B. Lercanidipine: a review of its use in hypertension. Drugs 2000 Nov; 60 (5): 1123-40
6. Herbette LG, Vecchiarelli M, Sartani A, et al. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance: updated molecular model to rationalize its pharmacokinetic properties. Blood Press 1998; 7 Suppl. 2: 10-7
7. Leonardi A, Poggesi E, Taddei C, et al. In vitro calcium antagonist activity of lercanidipine and its enantiomers. J Cardiovasc Pharmacol 1997; 29 Suppl. 1: S10-8
8. Testa R, Rimoldi E, Sironi G, et al. Hemodynamic effects and power spectral analysis of heart rate and arterial pressure variabilities induced by lercanidipine and its enantiomers in conscious dogs. J Cardiovasc Pharmacol 1997; 29 Suppl. 1: S78-85
9. Meredith PA. Lercanidipine: a novel lipophilic dihydropyrindine calcium antagonist with long duration of action and high vascular selectivity. Exp Opin Invest Drugs 1999; 8 (7): 1043-62
10. Sironi G, Colombo D, Greto L, et al. Antihypertensive activity of lercanidipine and its enantiomers in animal models. J Cardiovasc Pharmacol 1997; 29 Suppl. 1: S33-40
11. Guarneri L, Angelico P, Ibba M, et al. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Arzneimittel Forschung 1996; 46: 15-24
12. Angelico P, Guarneri L, Leonardi A, et al. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol 1999; 51: 709-14
13. van der Lee R, Pfaffendorf M, van Zwieten PA. The differential time courses of the vasodilator effects of various 1,4-dihydropyridines in isolated human small arteries are correlated to their lipophilicity. J Hypertens 2000 Nov; 18 (11): 1677-82
14. Ambrosioni E, Circo A. Activity of lercanidipine administered in single and repeated doses once daily as monitored over 24 hours in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1997; 29 Suppl. 2: S16-20
15. Macchiarulo C, Pieri R, Mitolo DC, et al. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordings. Curr Ther Res 2001; 62(4): 236-53
16. Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens 1998; 16 (Pt 1): 1831-8
17. Cavallini A, Terzi G. Effects of antihypertensive therapy with lercanidipine and verapamil on cardiac electrical activity in patients with hypertension: a randomized, double-blind pilot study. Curr Ther Res 2000 Jul; 61 (7): 477-87
18. Barbagallo Sangiorgi G, Putignano E, Calcara L, et al. Efficacy and tolerability of lercanidipine vs. captopril in patients with mild to moderate hypertension in a double-blind controlled study. J Cardiovasc Pharmacol 1997; 29 Suppl. 2: S36-9
19. De Giorgio LA, Orlandini F, Malasoma P, et al. Double-blind, crossover study of lercanidipine versus amlodipine in the treatment of mild-to-moderate essential hypertension. Curr Ther Res 1999 Oct; 60 (10): 511-20
20. James IGV, Jones A, Davies P. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002 Aug; 16 (8): 605-10
21. Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double-blind controlled study. J Cardiovasc Pharmacol 1997; 29 Suppl. 2: S26-30
22. Paterna S, Licata A, Arnone S, et al. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. J Cardiovasc Pharmacol 1997; 29 Suppl. 2: S50-3
23. Rimoldi E, Lumina C, Giunta L, et al. Evaluation of the efficacy and tolerability of two different formulations of lercanidipine versus placebo after once-daily administration in mild to moderate hypertensive patients. Curr Ther Res 1993 Aug; 54 (2): 248-53
24. Seravalle G, Stella ML, Foglia G, et al. Temporal profile of antihypertensive drug-induced regression of cardiac and vascular structural alterations in hypertension [abstract no. P0780]. J Hypertens 2002; 20 Suppl. 4: S190-1
25. Sánchez A, Sayans R, Alvarez JL, et al. Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril [abstract no. 12]. Fourth European Meeting on Calcium Antagonists; 1999 Oct 27-29; Amsterdam
26. Fogari R, Mugellini A. Corradi L, et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract no. P1.191]. J Hypertens 2000; 18 Suppl. 2: S65
27. Corsini A, Accomazzo MR, Canavesi M, et al. The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved? Blood Press 1998; 7 Suppl. 2: 18-22
28. Taddei S, Virdis A, Ghiadoni L, et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 2003; 41: 950-5
29. Rachmani R, Levi Z, Zadok BS, et al. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clin Pharmacol Ther 2002 Sep; 72 (3): 302-7
30. Incandela L, Belcaro G, Cesarone MR, et al. Oxygen-free radical decrease in hypertensive patients treated with lercanidipine. Int Angiol 2001 Jun; 20 (2): 136-40
31. Soma MR, Natali M, Donetti E, et al. Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br J Pharmacol 1998; 125: 1471-6
32. Sabbatini M, Leonardi A, Testa R, et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775-9
33. Sabbatini M, Vitaioli L, Baldoni E, et al. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. J Pharmacol Exp Ther 2000; 294: 948-54
34. Kanda T, Hayashi K, Ozawa Y, et al. Role of T-type calcium channels as a determinant of glomerular microcirculation and subsequent renal protection [abstract no. P0170]. J Hypertens 2002 Jun; 20 Suppl. 4: S48
35. Notarbartolo A, Rengo F, Scafidi V, et al. Long-term effects of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension. Curr Ther Res 1999 Apr; 60 (4): 228-36
36. Viviani GL. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J Cardiovasc Pharmacol 2002 Jul; 40 (1): 133-9
37. Fogari R, Malamani GD, Zoppi A, et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel-group study. Curr Ther Res Clin Exp 2000 Dec; 61: 850-62
38. Lund-Johansen P, Stranden E, Helberg S, et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens 2003 May; 21 (5): 1003-10
39. Harada N, Yamaguchi H, Shigematsu K, et al. Effects of lercanidipine, a novel calcium antagonist, on stroke-prone spontaneously hypertensive rats. SHR Congress; 1999 Aug 26-27; Sapporo, Japan
40. Amenta F, Leonardi A, Sabbatini M, et al. Glial-fibrillary acidic protein immunoreactive astrocytes in the brain of spontaneously hypertensive rats: sensitivity to pharmacological treatment [abstract]. 28th National Congress of the Italian Society of Histochemistry; 1999 Jun 2-4; Camerino, Italy
41. Guarneri L, Sironi G, Angelico P, et al. In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers. J Cardiovasc Pharmacol 1997; 29 Suppl. 1: S25-32
42. Bianchi G, Passoni A, Griffini PL. Effects of a new calcium antagonist, REC 15/2375, on cardiac contractility of conscious rabbits. Pharmacol Res 1989; 21 (2): 193-200
43. Grassi G, Seravalle G, Turri C, et al. Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension 2003 Mar; 41 (3): 558-62
44. Fogari R, Mugellini A, Zoppi A, et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003; 16 (7): 596-9
45. Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiovasc Pharmacol 1997; 29 Suppl. 2: S31-5
46. Barbagallo M, Barbagallo Sangiorgi G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000 Oct; 12 (5): 375-9
47. Romito R, Pansini MI, Perticone F, et al. Comparative effect of lercandipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercandipine in Adults (LEAD) study. J Clin Hypertens 2003; 5 (4): 249-53
48. Barrios V, Navarro A, Esteras A, et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002; 11 (2): 95-100
49. Cominacini L, Fratta Pasini A, Garbin U, et al. Antioxidant activity of different dihydropyridines. Biochem Biophys Res Commun 2003 Mar 21; 302 (4): 679-84
50. Lozano JV, Sanchis C, Llisterri JL. Efficacy of lercanidipine in poorly controlled hypertensive patients who follow a home blood pressure measurement training program [abstract no. R190]. J Hypertens 2002 Jun; 20 Suppl. 4: S376
51. Abellán Alemán J, Martínez García JF, Merino Sanchez J, et al. Evaluation of psychosomatic semiology in hypertensive patients treated with lercanidipine (LERCAPISCO study) [in Italian]. An Med Interna 2003; 20 (6): 287-91
52. 2+ antagonists on the renal arterial tree in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2002 Jan; 39 (1): 39-48
53. Zanchetti A, Cifkova R, Fagard S, et al. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. Journal of Hypertension 2003; 21: 1011-53
54. Robles NR, Ocon J, Campdera FG, et al. Lercanidipine in chronic renal failure (CRF) [abstract no. P2.225]. J Hypertens 2003; 21 Suppl. 4: S185
55. Pedrinelli R, Dell'Omo G, Nuti M, et al. Heterogenous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens 2003; 21: 1969-73
56. Guillen VF, Abellan J, Llisterri JL, et al. Efficacy and safety of Lercanidipine in combination with Enalapril in HBP: preliminary results of ZANYCONTROL Study Group [abstract no. P.212]. Am J Hypertens 2003; 16 (5 Suppl. 1): 115A
57. Barchielli M, Dolfini E, Farina P, et al. Clinical pharmacokinetics of lercanidipine. J Cardiovasc Pharmacol 1997; 29 Suppl. 2: S1-15
58. Napp Pharmaceuticals Ltd. Zanidip tablets: SPC from the eMC [online]. Available from URL: http://emc.vhn.net/eMC/assets/ c/html/DisplayDoc.asp? DocumentId=1234 [Accessed 2003 Oct 10]
59. Barchielli M, Leoni B, Perego R. Lercanidipine plasma levels monitoring in patients: pharmacokinetic contribution to the study Rec 15/2375-RIC1-0047: dose finding study with lercanidipine in angina pectoris. Double blind randomised multicentre trial. Milan: Recordati, 1999. (Data on file)
60. Klotz U. Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. Arzneimittel Forschung 2002; 52 (3): 155-61
61. Farina P, Tajana A, Barchielli M. et al. Effect of lercanidipine on CYP2D6 and CYP3A4 activities: in vitro/in vivo correlation [abstract], 9th North American International Society for the Study of Xenobiotics Meeting; 1999 Oct 24-28; Nashville. TN
62. Hedner T, Everts B, Kraizci H, et al. Enhanced blood pressure lowering effect in hypertensive patients on combined sildenafil and lercanidipine treatment [abstract no. P3.52]. 10th European Meeting on Hypertension; 2000 May 29-Jun 3; Goteborg, Sweden
63. Schwinger RHG, Schmidt-Mertens A. The new lipophillic calcium channel blocker lercanidipine combines high antihypertensive efficacy with low side effects [abstract no. P1-7]. Dtsch Med Wochenschr 2002; 127 Suppl. 1: S13
64. Calvo C, Hermida R, Navarro A. Results from the ZANyCAL study on the treatment of elderly hypertensive patients [abstract no. P343]. Cardiovasc Drugs Ther 2002 May; 16 Suppl. 1: 57
65. Roma J, Sobrino J, Plana J, et al. Treatment with lercanidipine during six months in hypertensive elderly patients (more than 60 years) [abstract no. R268]. J Hypertens 2002 Jun; 20 Suppl. 4: S391
66. Leonetti G, Magnani B, Pessina AC, et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002 Nov; 15 (11): 932-40
67. Ninci MA, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study. J Cardiovasc Pharmacol 1997; 29 Suppl. 2: S40-4
68. Cherubini A, Fabris F, Ferrari E, et al. Comparative effects of lercanidipine, lacidipine and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LEcandipine (ELLE) study. Arch Gerontol Geriatr 2003; 37: 203-12
69. Rengo F, Romis L. Activity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hypertension. J Cardiovasc Pharmacol 1997; 29 Suppl. 2: S54-8
70. A multicenter randomized, double-blind trial of the efficacy and safety of lercanidipine in patients with mild to moderate essential hypertension, uncontrolled on hydrochlorothiazide. Milan: Recordati S.p.A, 2000. (Data on file)
71. Cafiero M, Giasi M. Long-term (12-month) treatment with lercanidipine in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1997; 29 Suppl. 2: S45-9
72. Luque M, Ruilope LM, Tamargo J, et al. Drug surveillance study in patients with mild to moderate hypertension treated with lercanidipine: the Zanyten study [abstract no. P068]. J Hypertens 2002 Jun; 20 Suppl. 4: S163
73. Herrera J, Ghais Z, Gonzalez L. Antihypertensive treatment with a calcium channel blocker in postmenopausal women: prospective study in a primary health care setting [abstract no. P0680]. J Hypertens 2002 Jun; 20 Suppl. 4: S162
74. Leonetti G. The safety profile of antihypertensive drugs as the key factor for the achievement of blood pressure control: current experience with lercanidipine. High Blood Press 1999; 8: 92-101
75. Borghi C, Prandin MG, Dormi A, et al. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press 2003; 12 Suppl. 1: 1-8
76. Ramsay LE, Williams B, Johnston GD, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999 Sep 4; 319: 630-5
77. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003; 289 (19): 2560-75
78. Staessen JA, Wang J-G, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated 1 March 2003. J Hypertens 2003; 21: 1055-76
79. Sheinfeld GR, Bakris GL. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens 1999; 12: 80S-5S
80. Alderman M, Arakawa K, Beilin L, et al. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Sub-Committee. Blood Press 1999; 8 Suppl. 1: 9-43
81. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-65
82. Black HR, Elliot WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial [abstract]. JAMA 2003; 289 (16): 2073-82